Daratumumab, an anti-CD38 monoclonal antibody developed to target malignant plasma cells in multiple myeloma, was also reported to effectively treat refractory post-HSCT AIC in several recent case reports (16). The gene discussed is CD38; the disease is AL amyloidosis.